Baudax Bio Secures Pharmacy Supplier Agreement with Vizient Inc. for ANJESO®
July 20, 2020 07:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has entered into a...
Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2020 15:25 ET
|
Baudax Bio, Inc.
MALVERN, Pa., July 03, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation...
Baudax Bio Announces Full Commercial Launch of ANJESO™ and Receipt of Unique C-Code and Pass-Through Payment Status Effective July 1, 2020
June 15, 2020 07:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., June 15, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the commercial launch of...
Baudax Bio Secures $50 Million Credit Facility
June 01, 2020 07:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has closed on a...
Baudax Bio Reports First Quarter 2020 Financial Results
May 08, 2020 07:00 ET
|
Baudax Bio, Inc.
ANJESO™ Approved by FDA for the Management of Moderate to Severe Pain; Product Now Available for Ordering and Delivery for Customers Strengthened...
Baudax Bio Announces Presentation of New Phase IIIb ANJESO™ Data at Digestive Disease Week 2020
May 05, 2020 07:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., May 05, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced a virtual poster...
Baudax Bio Announces Change in Location of its 2020 Annual Meeting of Shareholders to its Corporate Headquarters
May 01, 2020 16:05 ET
|
Baudax Bio, Inc.
MALVERN, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on therapeutics for acute care settings, today announced that due to...
Baudax Bio Announces Presentation of New Phase IIIb ANJESO™ Data at the 45th Annual Regional Anesthesiology and Acute Pain Medicine Meeting
April 23, 2020 07:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced two virtual poster...
Baudax Bio Announces U.S. Availability of ANJESO™ (meloxicam) Injection for the Management of Moderate to Severe Pain
April 07, 2020 08:00 ET
|
Baudax Bio, Inc.
ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing Full Commercial Launch Expected to Commence by June 2020 MALVERN, Pa., April 07, 2020 (GLOBE...
Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2020 18:40 ET
|
Baudax Bio, Inc.
MALVERN, Pa., April 03, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation...